Sanofi (EPA:SAN) PT Set at €89.50 by UBS Group

UBS Group set a €89.50 ($104.07) price objective on Sanofi (EPA:SAN) in a research note published on Friday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts have also recently issued reports about the stock. HSBC set a €79.00 ($91.86) price objective on shares of Sanofi and gave the stock a neutral rating in a research report on Friday, August 2nd. Kepler Capital Markets set a €88.00 ($102.33) price objective on shares of Sanofi and gave the stock a buy rating in a research report on Friday, September 13th. Deutsche Bank set a €92.00 ($106.98) price objective on shares of Sanofi and gave the stock a buy rating in a research report on Monday, September 2nd. JPMorgan Chase & Co. set a €81.00 ($94.19) price objective on shares of Sanofi and gave the stock a neutral rating in a research report on Tuesday, July 30th. Finally, Credit Suisse Group set a €94.00 ($109.30) price objective on shares of Sanofi and gave the stock a buy rating in a research report on Friday, October 4th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of €88.97 ($103.45).

Sanofi stock opened at €83.38 ($96.95) on Friday. The stock’s fifty day moving average price is €82.34. Sanofi has a 12-month low of €63.09 ($73.36) and a 12-month high of €92.97 ($108.10).

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

See Also: What are Bollinger Bands?

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.